CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Phase 1 Completed 11 enrolled Viralytics

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.

Timeline

Start: 2018-01-29
Primary completion: 2019-05-22
Completion: 2019-05-22

Publications

Results Lutzky J, Sullivan RJ, Cohen JV, Ren Y, Li A, Haq R. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2023 Aug;149(9):6059-6066. doi: 10.1007/s00432-022-04510-3. Epub 2023 Jan 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gebasaxturev	Other / unclassified	1e+09 unknown	Intravenous
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	Intravenous

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Summary

Timeline

Publications

Drugs

Indications